Navigation Links
Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Date:7/31/2008

Summary: Phase III Pivotal Study of Ofatumumab in Refractory CLL Meets

Primary Endpoint

COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of the Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) to treat two groups of chronic lymphocytic leukemia (CLL) patients with high unmet medical need. At the interim analysis, the study met the primary endpoint in both populations and the results from the secondary endpoints also support the primary endpoint.

The activity of ofatumumab was evaluated in 154 patients in this interim analysis of whom 138 patients with refractory CLL were evaluable. About half of the patients (59) in the study were refractory to both fludarabine and alemtuzumab. The analysis also included a second group (79) who were refractory to fludarabine and considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes. An objective response rate of 51% (p<0.0001) consisting of 30 partial responses (PR) was achieved in the group of patients refractory to fludarabine and alemtuzumab. In the fludarabine refractory, alemtuzumab inappropriate patient group, an objective response rate of 44% (p<0.0001) was achieved, including 1 complete response (CR), and 34 PR. Achievement of the reported objective response rates are based on evaluations by an independent committee and are subject to review and confirmation by the regulatory authorities.

Ofatumumab was generally well tolerated by CLL patients in the study. The most frequently reported adverse events (those that occurred at a greater than 15% frequency) were: pyrexia, diarrhea, fatigue, cough, neutropenia, anemia and pneumonia. There were no unexpected safety findings. None of the 14 patients tested for human anti-human antibodies (HAHA) demonstrated their presence at 12 months.

A pre-B
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
2. Genmab Reaches Milestone in Ofatumumab Collaboration
3. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
4. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
5. Genmab Announces Updates on Phase III Cancer Studies
6. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
7. Bionomics Achieves US$1 Million Milestone Payment from Genmab
8. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
9. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
10. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
11. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... CHESTER, Pa. , Sept. 19, 2014 /PRNewswire/ ... launched two new variable angle plating systems featuring ... technology, surgeons can adapt screw trajectory to match ... towards specific fragments of bone. The systems are ... Foot & Ankle Society (AOFAS) and the International ...
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data ... devices market. The report provides value, ... volume (in units) within market categories ... Sigmoidoscopes, Esophagoscopes & Gastroscopes, Duodenoscopes, Laparoscopes, ...
(Date:9/19/2014)... , Sept. 19, 2014  For Cloud ... drug design and development, partnering is an integral ... is to design new drugs and identify early ... partners to further their development. The company also ... To support this business model, Cloud Pharmaceuticals will ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... 2010 Zimmer Holdings, Inc. (NYSE: ZMH ... today announced it has acquired Sodem Diffusion S.A., the ... Geneva, Switzerland.  The company will be re-named Zimmer Surgical, ... in Dover, Ohio.   "Adding SoPlus,s innovative ...
... 22, 2010 Watson Pharmaceuticals (NYSE: WPI ) ... of a novel oral contraceptive product – the first and ... and 0.025 mg ethinyl estradiol in chewable form, with four ... daily, the product is proven effective in lowering ...
Cached Medicine Technology:Zimmer Announces Acquisition of SoPlus Orthopaedic Surgical Power Tools Company 2Watson Announces Novel Oral Contraceptive Approval 2Watson Announces Novel Oral Contraceptive Approval 3Watson Announces Novel Oral Contraceptive Approval 4
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... that bacterial pneumonia can raise your risk of heart problems, ... and kill heart cells, increasing the chances of heart failure, ... report. In mice, monkeys and human heart tissue, researchers ... and they tried a vaccine that might one day prevent ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 At ... the nonprofit Seafood Nutrition Partnership (SNP) announced the ... Heart Healthy: A Cardiovascular Risk Reduction Program for ... women understand and mitigate their risk of heart ... to Action, a plan for addressing significant global ...
(Date:9/22/2014)... Burbank, CA (PRWEB) September 22, 2014 ... social and mobile recruiting, announced today an ... talent management solutions for the healthcare industry. ... to TweetMyJobs’ suite of social recruiting solutions ... management software designed specifically for healthcare organizations. ...
(Date:9/22/2014)... MAINE AND BOSTON -- In a collaboration that ... advance cancer research and patient care and accelerate ... Beth Israel Deaconess Medical Center (BIDMC) have established ... institutions, presidents announced today. , A recently signed ... Center to establish a comprehensive relationship in the ...
(Date:9/22/2014)... NCPDP, the not-for-profit pharmacy standards development ... 2014 Educational Summit , “Improving the Infrastructure for ... 11, 2014 at the Hyatt Regency Indianapolis. Steven ... Technology, Office of the National Coordinator for Health ... takes place right before NCPDP’s Work Group Meetings, ...
Breaking Medicine News(10 mins):Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 2Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 2Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 3Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 4Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 3Health News:NCPDP Educational Summit, Improving the Infrastructure for Continuity of Care, Features Keynote, Steven Posnack 2Health News:NCPDP Educational Summit, Improving the Infrastructure for Continuity of Care, Features Keynote, Steven Posnack 3
... Mary Bono Mack (CA-45) and Nita Lowey (NY-18) ... and well-being of American youth by reintroducing the ... The bipartisan legislation, broadly supported by such organizations ... cross-sector collaboration for improving the health of young ...
... (Nasdaq: MDTH ), (the "Company") a healthcare ... and treatment of cardiovascular disease, today announced that it has ... quarter ended March 31, 2009 and the filing of its ... as a result of an ongoing internal assessment by the ...
... nation,s leading cardioelectrophysiologists, has joined The Mount Sinai Medical Center as ... ... (Vocus)-- Vivek Y. Reddy, M.D., one of the nation,s leading cardioelectrophysiologists, ... of Electrophysiology Laboratories. His appointment becomes effective July 1., , ...
... C. Kolars, M.D., has been named the University ... for Education and Global Initiatives, effective June 1, pending the ... the Medical School,s lead for the oversight and expansion of ... James O. Woolliscroft , M.D., the medical school,s ...
... Fund now has within its reach the potential to ... meeting in Geneva, the Board of Directors of the ... Fund), today agreed to enhance the Fund,s response to ... prevent mother-to-child transmission of HIV (PMTCT), thereby opening the ...
... of the Clopidogrel Medco Outcomes Study presented today during SCAI,s ... may be reduced when taken concurrently with commonly used heartburn ... patients taking clopidogrel and a PPI experienced a: , ... 50% increase in the combined risk of hospitalization for heart ...
Cached Medicine News:Health News:Bono Mack, Lowey Introduce Bill To Improve the Health of Youth 2Health News:Vivek Y. Reddy, M.D., Joins The Mount Sinai Medical Center as Director of Electrophysiology Laboratories 2Health News:Vivek Y. Reddy, M.D., Joins The Mount Sinai Medical Center as Director of Electrophysiology Laboratories 3Health News:Joseph C. Kolars, M.D., to be U-M Medical School's First Senior Associate Dean for Education and Global Initiatives 2Health News:GAA Applauds Global Fund's Decision to Accelerate Support for Treatment Strategies to Prevent Mother-to-Child Transmission of HIV 2Health News:SCAI Statement on 'A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study' 2
... to 17 parameters from just 95 ... blood gases, as well as any ... metabolite parameters. Unique technology reduces to ... substances have on the accuracy of ...
... a sophisticated whole blood analysis system that ... also satisfying the stringent requirements of the ... contains all of the components of a ... the sampling unit, all of the sensors ...
... The Rapidlab 800 System is a ... key critical care whole blood parameters in ... modular design allows the basic blood gas ... to include electrolytes, metabolites and CO-oximetry in ...
This compact, easy-to-operate analyzer delivers basic blood gas, ISEs with direct measured total hemoglobin and saturated oxygen. Use it as a cost effective backup for the central lab or for remote p...
Medicine Products: